血友病A:一种理想的疾病,用于产前治疗
Christopher D Porada1, Anthony Atala1, Graça Almeida-Porada1
1Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA.
Prenatal diagnosis
|June 11, 2025
概括
产前基因疗法为A型血友病 (HA) 提供了潜在的治疗方法. 在出生前使用介质干细胞 (MSC) 传递因子VIII (FVIII) 基因可以为HA患者提供终身治疗.
科学领域:
- 再生医学是一种再生医学.
- 基因治疗 基因治疗
- 血液学 血液学 血液学
背景情况:
- 血友病A (HA) 是一种常见的遗传性出血障碍.
- 目前的治疗方法涉及频繁的第八因子 (FVIII) 输注,这很昂贵,可能会引起免疫反应.
- 现有的疗法并非全方位可用,需要终身坚持.
研究的目的:
- 探索孕前基因疗法治疗血友病A (HA) 的可行性.
- 为了突显产前治疗方法对HA的优势.
- 引入一种羊模型来研究HA及其在子宫内治疗的潜力.
主要方法:
- 对血友病A (HA) 的羊模型的开发.
- 使用介质干细胞 (MSC) 作为FVIII基因传递的载体.
- 研究在子宫内基因疗法的潜力,以实现对HA的治愈.
主要成果:
- 这项研究的重点是针对HA的产前干预的潜力.
- 介酶干细胞 (MSC) 被提出为FVIII基因的有效传递载体.
- 为了研究这种产前方法的有效性,开发了一种绵羊模型.
结论:
- 使用MSCs的产前基因疗法为治疗血友病A (HA) 的一次性治疗提供了一个有希望的策略.
- 这种方法可以克服当前终身治疗的局限性.
- 在开发的绵羊模型中进行进一步的研究是有必要的,以验证这种治疗策略.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
Rh Blood Group
1.4K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.4K
Disorders of Hemostasis
738
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
738
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K
Extrinsic and Intrinsic Pathways of Hemostasis
6.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.3K


